Jane E. Minturn, MD, PhD

Jane E. Minturn, MD, PhD, is an attending physician at CHOP’s Cancer Center who specializes in treating children with brain tumors.

Appointments and Referrals: 1-800-TRY-CHOP

  • Background

    I'm part of a small group that focuses specifically on brain tumors. Our multidisciplinary team includes oncologists, a neurologist, neurosurgeons, a radiation oncologist, social workers and a neuropsychologist, along with skilled nurse practitioners. This is the broad spectrum of expertise that The Children's Hospital of Philadelphia brings to treating its patients with brain tumors.

    Treating cancer is a team effort at Children's Hospital, and we consider patients and their families a part of the team. Since our young patients are dependent on their parents for medical decision making, I try to give them a sense of some control over their disease, communicating in an age appropriate manner. Kids do much better, even when facing death, when they are part of the treatment plan and "secrets" are not kept from them.

    I do both basic science and clinical research that focuses on developmental therapeutics in tumors of the nervous system. In particular I and my colleagues are looking at signal transduction in neuroblastoma and medulloblastoma. We are evaluating the biological effects of neurotrophin receptor expression on the growth properties of these tumors. Neurotrophins are able to signal certain cells to survive, mature or grow. The Trk family of neurotrophin receptors plays a critical role in these diverse behaviors.

    We recently completed a clinical trial that targeted these receptors to inhibit signaling in neuroblastoma. The results are promising that this could be a therapeutic target for high risk neuroblastoma. We also are studying the way that Trk receptor molecules located on the surface of medulloblastoma cells regulate tumor growth and development. These studies may help to identify new therapeutic targets in the Trk signaling pathways.

    As part of our approach to identifying new treatments for children with brain tumors, we are members of the multi-institutional Pediatric Brain Tumor Consortium (PBTC) and the Developmental Therapeutics Children's Oncology Group. These groups are involved in early phase clinical trials for relapsing and refractory brain tumors, with a particular focus on testing new, targeted treatments in children with brain tumors.

    Our Children's Hospital team has partnered with drug development groups, and we are rapidly identifying drugs that show promise in patients with brain tumors who have no other curable option. There is a sense of urgency in our group -- we don't randomly test drugs but work collaboratively with laboratory scientists and drug development companies on rational, biologically-based targets. The best example of this is a drug for medulloblastoma that was recently rapidly brought to a PBTC clinical trial.

    There is huge progress in getting promising drugs to kids with cancer. Through our cooperative group consortia, the pace is much more rapid than in past years, and Children's Hospital is a major part of the effort to help bring new agents to children with brain tumors.

     

  • Education and Training

    Medical School

    Yale University School of Medicine (MD), New Haven, Conn.

    Residency

    The Children's Hospital, Boston, Mass.

    Fellowship

    Hematology/Oncology, The Children's Hospital of Philadelphia, Philadelphia, Pa.

    Board Certification

    American Board of Pediatrics
    American Board of Pediatrics/Pediatric Hematology-Oncology

    Undergraduate Degree

    University of Southern California (BS, psychobiology), Los Angeles, Calif.

    Graduate Degree

    Yale University (PhD, neurobiology), New Haven, Conn.

  • Titles and Academic Titles

    Attending physician

    Assistant Professor of Pediatrics, Perelman School of Medicine at the University of Pennsylvania

  • Conditions Treated
  • Centers and Programs
  • Publications

    Books

    Chapters
    2011

    Sievert AJ, Minturn JE. Brain tumors. In: Florin TA, Ludwig S, editors. Netter's pediatrics. Philadelphia: Elsevier Publishing; 2011.

    2008

    Fisher MJ, Minturn J, Phillips PC. Brain tumors. In: Brodeur GM, Manno CS, editors. Pediatric hematology/oncology: the requisites in pediatrics. Philadelphia: C.V. Mosby Publishing; 2008.

    Minturn JE. Teratoma. In: Schwartz MW, editor. The 5-minute pediatric consult. 5th ed. Philadelphia: Lippincott Williams & Wilkins; 2008. p. 840-41.

    2005

    Minturn JE. Teratoma. In: Schwartz MW, editor. The 5-minute pediatric consult. 5th ed. Philadelphia: Lippincott Williams & Wilkins; 2005. p. 834-35.

    2002

    Minturn JE, Friedman DL. Teratoma. In: Schwartz MW, editor. The 5-minute pediatric consult. 5th ed. Philadelphia: Lippincott Williams & Wilkins; 2002. p. 812-13.

    Minturn JE. Idiopathic thrombocytopenic purpura. In: Schwartz MW, editor. The 5-minute pediatric consult. 5th ed. Philadelphia: Lippincott Williams & Wilkins; 2002. p. 464-65.

    Minturn JE, Kelly KM. Hemophilia. In: Schwartz MW, editor. The 5-minute pediatric consult. 5th ed. Philadelphia: Lippincott Williams & Wilkins; 2002. p. 420-21.

    Minturn JE, Kelly KM. Aplastic anemia. In: Schwartz MW, editor. The 5-minute pediatric consult. 5th ed. Philadelphia: Lippincott Williams & Wilkins; 2002. p. 130-31.

    Abstracts

    2010

    Minturn JE, Evans AE, Villablanca JG, Yanik GA, Park JR, et al. Phase I trial of lestaurtinib for children with refractory neuroblastoma [abstract]. Advances in Neuroblastoma Research; 2010 Jun 21-24; Stockholm, Sweden. 

    Ho R, Minturn JE, Brown V, Iyer R, Sheen C, Hulitt J. Effect of phosphoinositide-3-kinase (PI3K) and mTOR dual inhibitors in human neuroblastomas [abstract]. Advances in Neuroblastoma Research; 2010 Jun 21-24; Stockholm, Sweden.

    Tetri LH, Ho R, Simpson AM, Iyer R, Minturn JE, Brodeur GM. Expression and function of RET in neuroblastoma cell lines [abstract]. Advances in Neuroblastoma Research; 2010 Jun 21-24. Stockholm, Sweden.

    Simpson AM, Light JE, Minturn JE, Ho R, Iyer R, Varela CR, et al. TrkAIII isoform expression is associated with aggressive behavior in human neuroblastomas [abstract]. Advances in Neuroblastoma Research; 2010 Jun 21-24; Stockholm, Sweden.

    Light JE, Koyama H, Gordin E, Minturn JE, Iyer R, Ho R, et al. Clinical significance of Trk family gene expression in neuroblastomas [abstract]. Advances in Neuroblastoma Research; 2010 Jun 21-24; Stockholm, Sweden.

    Mangino J, Iyer R, Chorny M, Alferiev I, Minturn JE, Ho R, et al. Nanoparticle delivery of the Trk inhibitor lestaurtinib in neuroblastomas [abstract]. Advances in Neuroblastoma Research; 2010 Jun 21-24; Stockholm, Sweden.

    Redden R, Iyer R, Urganski L, Minturn JE, Brodeur GM, Doolin E. Use of a microgravity culture system to assess biological behavior in neuroblastoma cell lines [abstract]. Advances in Neuroblastoma Research; 2010 Jun 21-24; Stockholm, Sweden.

    Minturn JE, Villablanca J, Yanik GA, Park JR, Groshen SG, Hellriegel ET, et al. Phase I trial of lestaurtinib for children with refractory neuroblastoma: new approaches to neuroblastoma therapy (NANT) study [abstract]. American Society for Clinical Oncology Annual Meeting; 2010 Jun 4-8; Chicago, IL.

    Doolin EJ, Redden R, Minturn JE, Brodeur GM. Microgravity culture provides a measurable clinical behavior of neuroblastoma [abstract]. American Pediatric Surgical Association Annual Meeting. 2010 May 16-19; Orlando, FL.

    Norris R, Minturn JE, Brodeur GM, Maris JM, Adamson PC. Preclinical evaluation of lestaurtinib (CEP-701) with the retinoids for neuroblastoma [abstract]. American Association for Cancer Research; 2010 Apr 17-21; Washington, DC.

    2009

    Berry RM, Rosenblatt M, Brodeur GM, Minturn JE, Wolf B, Rogers J, et al. Analysis of Trk signaling pathways using rapid Western blot analysis in combination with kinase inhibitors and RNAi [abstract]. Society for Neuroscience; 2009 Oct 17-21; Chicago, IL.

    Ho R, Minturn JE, Brown VI, Iyer R, Sheen C, Hulitt J, et al. Dual inhibition of phosphoinositide-3-kinase (PI3K) and mTOR show enhanced efficacy in human neuroblastomas [abstract]. American Association for Cancer Research; 2009 Apr 18-22; Denver, CO.

    Light JE, Iyer R, Ho R, Varela CR, Killa V, Brodeur GM, et al. Inhibition of Trk-mediated signaling through PI3K but not MEK/ERK impairs cell survival in medulloblastoma [abstract]. American Association for Cancer Research; 2009 Apr 18-22; Denver, CO.

    Iyer R, Minturn JE, Ho R, Varela C, Simpson AM, Light JE. Characterization of Trk inhibitor, AZ64, in pre-clinical models of neuroblastoma [abstract]. American Association for Cancer Research; 2009 Apr 18-22; Denver, CO.

    Papers

    2011

    Long PM, Stradecki HM, Minturn JE. Wesley UV, Jaworski DM. Differential aminoacylase expression in neuroblastoma. Int J Cancer. 2011 Sep 15;129(6):1322-30. doi: 10.1002/ijc.25798. Epub 2011 Apr 1. Cited in PubMed: PMID 21128244. Read the abstract

    deBlank PM, Minturn JE. A rare case of ectopic recurrence of a craniopharyngioma diagnosed 17 years after initial presentation. J Pediatr Oncol. 2011 Jul;33(5):392-7. Cited in PubMed: PMID 21602726. Read the abstract

    Ho R, Minturn JE, Simpson AM, Iyer R, Light JE, Evans AE, et al. The effect of P75 on Trk receptors in neuroblastomas. Cancer Lett. 2011 Jun 1;305(1):76-85. Epub 2011 Mar 17. Cited in PubMed: PMID 21419569. Read the abstract

    Norris RE, Minturn JE, Brodeur GM, Maris JM, Adamson PC. Preclinical evaluation of lestaurtinib (CEP-701) in combination with retinoids for neuroblastoma. Cancer Chemother Pharmacol. Epub 2011 Apr 12. Cited in PubMed: PMID 21484309. Read the abstract

    Haas-Kogan DA, Banerjee A, Poussaint TY, Kocak M, Prados MD, Geyer JR, et al. Phase II trial of tipifarnib and radiation in children with newly diagnosed diffuse intrinsic pontine gliomas. Neuro Oncol. 2011 Mar;13(3):298-306. Cited in PubMed: PMID 21339191. Read the abstract.

    Minturn JE, Evans AE, Villablanca JG, Yanik GA, Park JR, Shusterman S, et al. Phase I trial of lestaurtinib for children with refractory neuroblastoma: a new approaches to neuroblastoma therapy consortium study. Cancer Chemother Pharmacol. Epub 2011 Feb 22. Cited in PubMed: PMID 21340605. Read the abstract

    Parsons DW, Li M, Zhang X, Jones S, Leary RJ, Lin JC, et al. The genetic landscape of the childhood cancer medulloblastoma. Science. 2011 Jan 28;331(6016):435-9. Epub 2010 Dec 16. Cited in PubMed: PMID 21163964. Read the article
     

    Minturn JE, Janss AJ, Fisher PG, Allen JC, Patti R, Phillips PC, et al. A phase II study of metronomic oral topotecan for recurrent childhood brain tumors. Pediatr Blood Caner. 2011 Jan;56(1):39-44. Cited in PubMed: PMID 21108437. Read the abstract

    2010

    Long PM, Stradecki HM, Minturn JE, Wesley UV, Jaworski DM. Differential aminoacylase expression in neuroblastoma. Int J Cancer. 2010 Dec 2. Read the abstract

    Minturn JE, Janss AJ, Fisher PG, Allen JC, Patti R, Phillips PC, Belasco JB. A phase II study of metronomic oral topotecan for recurrent childhood brain tumors. Pediatr Blood Cancer. 2011 Jan;56(1):39-44. Read the abstract

    Posters and Presentations

    2009

    Minturn JE. Preclinical and early phase clinical experience with lestaurtinib in refractory neuroblastoma [invited lecture]. Cephalon, Inc.; 2009 Jun 29; West Chester, Pa.

  • Editorial and Academic Positions

    Editorial positions

    Reviewer

    Clinical Cancer Research
    Journal of Neuro-Oncology
    Neuropediatrics
    Pediatric Blood & Cancer

    Academic positions

    2010, Proton Therapy Triage Committee
    2008-present, Pediatric Protocol Review Committee, Oncology
    2006-present, Pediatric Residency Program Faculty Interviewer